Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ACACB | O00763 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9784096 | 0.85 | ACACB (0.46) | POLBACACBPPARAPPARGELANE | |
| SCHEMBL482856 | 0.85 | PPARA (0.51) | POLBACACBPPARAPPARGHTT | |
| SCHEMBL11218545 | 0.83 | CA2 (0.52) | PPARAPPARGCYP1A2CYP3A4 | |
| SCHEMBL11218542 | 0.83 | PPARA (0.46) | POLBACACBPPARAPPARGELANE | |
| SCHEMBL7983265 | 0.83 | POLB (0.56) | POLBACACBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10389748 | 0.81 | ALDH1A1 (0.53) | POLBACACBPPARAPPARGSMN1; SMN2 | |
| SCHEMBL4458742 | 0.81 | PPARA (0.49) | ACACBPPARAPPARGELANEHTT | |
| SCHEMBL19619634 | 0.81 | NPC1 (0.50) | ACACBPPARAPPARGHTTMAPT | |
| SCHEMBL7502088 | 0.81 | CYP4F2 (0.56) | ACACBPPARAPPARGHTTSMN1; SMN2 | |
| SCHEMBL4451939 | 0.80 | PPARA (0.44) | POLBACACBPPARAPPARGELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2007077140-A1 | HYDROXY-NOREPHEDRINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | BASF AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | POLB 3271/4885ACACB 1954/4885PPARA 623/4885 |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | POLB 3776/4885ACACB 2091/4885PPARA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.